Literature DB >> 21258254

The prognostic impact of cigarette smoking on patients with non-small cell lung cancer.

Ryo Maeda1, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai.   

Abstract

INTRODUCTION: The purposes of this study are to investigate the association between cigarette smoking and clinicopathological characteristics of patients with non-small cell lung cancer (NSCLC) and to evaluate its significance as a predictor of recurrence after resection.
METHODS: A total of 2295 consecutive patients with NSCLC underwent complete resection with systematic node dissection between August 1992 and December 2006 at the National Cancer Center Hospital East.
RESULTS: A statistically significant difference in the 5-year overall survival rate was observed between never and ever smokers in patients with stage I (92% and 76%, respectively, p < 0.001) NSCLC, whereas no difference was observed in stage II (57% and 52%, respectively, p = 0.739) and stage III (30% and 33%, respectively, p = 0.897). In patients with stage I NSCLC, 5-year recurrence-free proportions (RFPs) for never and ever smokers were 89% and 80%, respectively (p < 0.001). In contrast, the 5-year RFPs for never smokers were lower than those for ever smokers in stage II (44% and 60%, respectively, p = 0.049) and stage III (17% and 31%, respectively, p = 0.004). In stage I patients, significant difference in 5-year RFP was observed between never and ever smokers (89% and 83%, respectively) in patients with adenocarcinoma, but not in patients with nonadenocarcinoma (82% and 76%, respectively).
CONCLUSIONS: Smoking history showed different impact on postoperative recurrence in patients with NSCLC between stage I and stages II and III, and depending on histology in stage I patients. Disease stages should be considered while evaluating smoking history as a predictor of recurrence.

Entities:  

Mesh:

Year:  2011        PMID: 21258254     DOI: 10.1097/JTO.0b013e318208e963

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

1.  Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.

Authors:  Rebecca Heist; Christopher G Azzoli
Journal:  Oncologist       Date:  2013-11-25

2.  Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans' Affairs Central Cancer Registry (VACCR) cohort analysis.

Authors:  Vijaya Raj Bhatt; Rishi Batra; Peter T Silberstein; Fausto R Loberiza; Apar Kishor Ganti
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

3.  Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery.

Authors:  Satoshi Shiono; Masato Katahira; Masami Abiko; Toru Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-08-02

4.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

5.  High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases.

Authors:  Jian-Fei Zhu; Ling Cai; Xue-Wen Zhang; Yin-Sheng Wen; Xiao-Dong Su; Tie-Hua Rong; Lan-Jun Zhang
Journal:  Chin J Cancer       Date:  2013-08-19

6.  Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.

Authors:  Naozumi Hashimoto; Akira Ando; Shingo Iwano; Koji Sakamoto; Shotaro Okachi; Asuka Matsuzaki; Yu Okada; Kenji Wakai; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2018-01-05       Impact factor: 3.317

7.  Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer.

Authors:  Yen-Kuang Lin; Han-Lin Hsu; Wei-Cheng Lin; Jer-Hwa Chang; Yw-Chun Chang; Chia-Lun Chang; Kevin Sheng-Po Yuan; Alexander T H Wu; Szu-Yuan Wu
Journal:  Oncotarget       Date:  2017-05-23

8.  Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Chin Kook Rhee; Yong Hyun Kim; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Sang Haak Lee; Seung Joon Kim; Hyoung Kyu Yoon; Tae-Jung Kim; Kyo Young Lee
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

9.  Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients.

Authors:  Naozumi Hashimoto; Asuka Matsuzaki; Yu Okada; Naoyuki Imai; Shingo Iwano; Kenji Wakai; Kazuyoshi Imaizumi; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2014-02-05       Impact factor: 3.317

10.  Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer.

Authors:  Yusuke Takahashi; Koji Sakaguchi; Hirotoshi Horio; Kyoko Hiramatsu; Shunsuke Moriya; Keiichi Takahashi; Masao Kawakita
Journal:  Br J Cancer       Date:  2015-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.